1. Anti-biofilm activity of carvacrol-thymoquinone nanocarriers on vulvovaginal candidiasis isolates.
- Author
-
Hajiaghaalizadeh M, Sheikharabi M, Jazi MS, Alhashem R, and Hosseini SS
- Subjects
- Humans, Female, Drug Carriers chemistry, Candida glabrata drug effects, Monoterpenes pharmacology, Monoterpenes chemistry, Candida drug effects, Biofilms drug effects, Candidiasis, Vulvovaginal microbiology, Candidiasis, Vulvovaginal drug therapy, Antifungal Agents pharmacology, Cymenes pharmacology, Microbial Sensitivity Tests, Benzoquinones pharmacology, Benzoquinones chemistry, Nanoparticles chemistry, Candida albicans drug effects
- Abstract
Given the recurrent nature of vulvovaginal candidiasis (VVC), the restricted availability of effective antifungal agents, and the recent rise in drug resistance, this study sought to assess the antifungal efficacy of carvacrol-thymoquinone delivered via a nanocarrier on Candida isolates obtained from patients with VVC. Isolates were identified using phenotypic and genotypic methods. Nanocarriers were synthesized using the thin-film hydration method. The antifungal activity of carvacrol-thymoquinone was evaluated using the broth microdilution method (CLSIM27-A3). The impact of nanocarriers on the biofilm formation capabilities of Candida isolates was assessed using the MTT assay. Data were analyzed using the Mann-Whitney U test. The nanocarrier exhibited a spherical morphology with a diameter measuring 50 nm. The nano-formulated drug combination could inhibit biofilm formation in C. albicans at half the minimum inhibitory concentration and in C. glabrata at the minimum inhibitory concentration. Our results suggest that the carvacrol-thymoquinone nanocarrier can be studied further in vivo for potential use in the treatment of recurrent VVC., Competing Interests: Declaration of competing interest The authors have no conflict of interest., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF